CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Mehta, Paul ; Horton, D. Kevin ; Kasarskis, Edward J. ; Tessaro, Ed ; Eisenberg, M. Shira ; Laird, Susan ; Iskander, John
• Description:
  Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a rapidly progressive fatal neurologic disease. Currently, there is no cure for ALS and the available treatments only extend life by an average of a few months. The majority of ALS patients die within 2-5 years of Diagnosis, though survival time varies depending on disease progression (1,2). For approximately 10% of patients, ALS is familial, meaning it and has a genetic component; the remaining 90% have sporadic ALS, where etiology is unknown, but might be linked to environmental factors such as chemical exposures (e.g., heavy metals, pesticides) and occupational History (3).
• Subjects:
  Aged Amyotrophic Lateral Sclerosis Forecasting Humans Male Middle Aged Population Surveillance Prevalence Registries Risk Factors White People

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 66(50):1379-1382.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6650a3
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  29267263
• Pubmed Central ID:
  PMC5751576
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  4 pdf pages
• Volume:
  66
• Issue:
  50
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:116ba7017b9a31c3d112d95f21fc2de1e60ce959bf919986e0571b2f5d8d6b94ae256e1e905a334627cda82956fb18bcd811795cd05843a4fc70c357052dfa8c
• Download URL:
  https://stacks.cdc.gov/view/cdc/54321/cdc_54321_DS1.pdf
• File Type:
  [PDF - 107.88 KB ]